Effect of rhBNP on the therapeutic efficacy,cardiac function and inflammatory factors in patients with dilated cardiomyopathy and chronic heart failure
10.3969/j.issn.1008-0074.2025.03.08
- VernacularTitle:rhBNP对扩张型心肌病合并慢性心力衰竭患者疗效、心功能及炎症因子的影响
- Author:
Xiao-hua ZHANG
1
;
Xiao-dong ZHANG
1
;
Guo-hua CHANG
1
Author Information
1. 东营市东营区人民医院心血管内科,山东东营 257000
- Publication Type:Journal Article
- Keywords:
Cardiomyopathy,dilated;
Chronic heart failure;
Recombinant human brain natriuretic peptide
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2025;34(3):322-327
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of recombinant human brain natriuretic peptide(rhBNP)on the efficacy,inflammatory factors and cardiac function in patients with dilated cardiomyopathy(DCM)and chronic heart failure(CHF).Methods:This randomized controlled study enrolled 130 patients with DCM and CHF admitted to Dongy-ing District People's Hospital of Dongying City between February 2017 and December 2018.Patients were divided into intervention group(n=65)and control group(n=65).Patients in control group received conventional treat-ment,while those in the intervention group was given additional rhBNP treatment,both groups were treated for 4 weeks.The total effective rate,cardiac function indicators,levels of inflammatory factors and blood lipids,as well as incidence of adverse reactions,were compared between the two groups.Results:The total effective rate(95.38％vs.76.92％,P＜0.001)of the intervention group was significantly higher than that of the control group.After treatment,compared to patients in the control group,those in the intervention group had significant higher left ventricular ejection fraction(LVEF)[(53.21±3.57)％vs.(45.39±2.56)％]and interleukin(IL)-10[(79.55±13.98)pg/ml vs.(69.32±13.86)pg/ml],and significant lower left ventricular end-systolic diameter(LVESd)[(35.25±3.19)mm vs.(40.34±3.09)mm],left ventricular end-diastolic diameter(LVEDd)[(43.29±4.87)mm vs.(50.18±4.21)mm],IL-18[(212.19±24.28)pg/ml vs.(257.98±39.72)pg/ml],and high sensitive C reactive protein(hsCRP)[(11.39±2.29)mg/L vs.(16.59±2.83)mg/L](P＜0.001 all).There was no significant difference in the incidence of adverse reactions between the two groups(P=0.753).Conclusion:The use of the rhBNP based on routine therapy for the treatment of dilated cardiomyopathy and chronic heart failure could effectively improve cardiac function and reduce levels of inflammatory factors.Additionally,it has a high safety profile.
